- Home
- EBMT vs PBYI Comparison
EBMT vs PBYI Comparison
Compare EBMT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- PBYI
- Stock Information
- Founded
- EBMT 1922
- PBYI 2010
- Country
- EBMT United States
- PBYI United States
- Employees
- EBMT N/A
- PBYI N/A
- Industry
- EBMT Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EBMT Finance
- PBYI Health Care
- Exchange
- EBMT Nasdaq
- PBYI Nasdaq
- Market Cap
- EBMT 139.5M
- PBYI 153.2M
- IPO Year
- EBMT N/A
- PBYI N/A
- Fundamental
- Price
- EBMT $15.25
- PBYI $2.97
- Analyst Decision
- EBMT
- PBYI Strong Buy
- Analyst Count
- EBMT 0
- PBYI 1
- Target Price
- EBMT N/A
- PBYI $7.00
- AVG Volume (30 Days)
- EBMT 21.3K
- PBYI 821.3K
- Earning Date
- EBMT 01-28-2025
- PBYI 02-27-2025
- Dividend Yield
- EBMT 3.75%
- PBYI N/A
- EPS Growth
- EBMT N/A
- PBYI 492.79
- EPS
- EBMT 1.09
- PBYI 0.47
- Revenue
- EBMT $80,038,000.00
- PBYI $243,569,000.00
- Revenue This Year
- EBMT N/A
- PBYI N/A
- Revenue Next Year
- EBMT $8.17
- PBYI N/A
- P/E Ratio
- EBMT $14.03
- PBYI $6.38
- Revenue Growth
- EBMT N/A
- PBYI 6.30
- 52 Week Low
- EBMT $12.32
- PBYI $2.23
- 52 Week High
- EBMT $17.62
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- EBMT 45.92
- PBYI 45.95
- Support Level
- EBMT $14.35
- PBYI $2.92
- Resistance Level
- EBMT $15.52
- PBYI $4.06
- Average True Range (ATR)
- EBMT 0.45
- PBYI 0.27
- MACD
- EBMT 0.08
- PBYI -0.03
- Stochastic Oscillator
- EBMT 72.00
- PBYI 4.39
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.